Immuno Oncology Assays Market by Product (Consumables, Software), Technology (Immunoassay, Flow Cytometry, PCR, Next Generation Sequencing), Indication (Lung Cancer, Colorectal Cancer), Application (Research, Clinical Diagnostics) - Global Forecast to 2024
[108 Pages Report] The market for immuno-oncology assays is expected to reach USD 5.9 billion by 2024 from USD 2.9 billion in 2018, at a CAGR of 12.7% during the forecast period. The growth of this market is primarily driven by factors such as the increasing adoption of targeted therapy over traditional therapy and increasing demand for mAbs. However, the high cost of immunotherapy treatment and the high attrition rate in the product development cycle are the major factors that are expected to restrain the growth of this market during the forecast period.
By product, the consumables segment is expected to be the fastest growing in the market during the forecast period.
Based on products, the immuno-oncology assays market is segmented into consumables and software. The consumables segment dominated the market with the largest share in 2018; this segment is also expected to register the highest CAGR during the forecast period. The large share of this segment can be attributed to the availability of a wide range of reagents and kits, increasing use of reagents in different oncology therapeutic treatments, increasing research on cancer immunotherapy biomarkers and its applications in drug development, and easy accessibility to a wide range of reagents.
By application, the research applications segment is growing at the highest rate.
Based on application, the immuno-oncology assays market is segmented into research applications and clinical diagnostics. Research applications dominated the market with the largest share in 2018. It is also projected to be the fastest-growing segment during the forecast period. The rising prominence of biomarker-based drug development and clinical trials and the emergence of cancer immunotherapy are the key factors driving market growth.
Asia Pacific to grow at the highest CAGR during the forecast period
The immuno-oncology assays market is divided into four major regions— North America, Europe, Asia Pacific, and the Rest of the World (RoW).
Asia Pacific is estimated to grow at the highest CAGR during the forecast period. The growing number of CROs in the region, increasing awareness about early detection of cancer, and the shift of manufacturers’ and suppliers’ focus from developed economies to emerging economies are some factors supporting the growth of this region.
Key Market Players
The key players operating in the immuno-oncology assays market are Thermo Fischer Scientific (US), Roche Diagnostics (Switzerland), Agilent Technologies (US), and Illumina (US).
Recent Developments:
- In 2018, Roche collaborated with SQZ Biotech to develop antigen presenting cells-based immune-oncology treatments.
- In 2018, Illumina launched its TruSight Oncology 500 assay, which is used to identify known and emerging tumor biomarkers.
- In 2018, Roche acquired Tusk Therapeutics to expand its oncology product portfolio.
- In 2018, Agilent acquired ACEA Biosciences (US). This acquisition will help both the companies to focus on real-time, live-cell analyzes through their expertise in cellular function and metabolism measurements.
- In 2016, Thermo Fisher collaborated with Invivoscribe Technologies to develop NGS-based in vitro diagnostic oncology tests.
Key questions addressed by the report:
- Who are the major market players in the immuno-oncology assays market?
- What are the regional growth trends and the largest revenue-generating regions for the immuno-oncology assays market?
- What are the major drivers and challenges in the immuno-oncology assays market?
- What are the major product segments in the immuno-oncology assays market?
- What are the major application segments in the immuno-oncology assays market?
- What are the major technology segments in the immuno-oncology assays market?
- What are the major indications for immuno-oncology assays?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 13)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Covered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. - 16)
2.1 Primary Data
2.1.1 Key Data From Primary Sources
2.1.2 Key Industry Insights
2.2 Secondary Data
2.2.1 Key Data From Secondary Sources
2.3 Market Size Estimation
2.4 Market Breakdown and Data Triangulation
2.4.1 Assumptions for the Study
3 Executive Summary (Page No. - 23)
4 Premium Insights (Page No. - 27)
4.1 Immuno-Oncology Assays: Market Overview
4.2 North America: Immuno-Oncology Assays Market, By Product and Country (2018)
4.3 Immuno-Oncology Assays Market, By Application (2018 vs 2024)
4.4 Immuno-Oncology Assays Market, By Technology (2018 vs 2024)
4.5 Geographical Snapshot of the Immuno-Oncology Assays Market
5 Market Overview (Page No. - 30)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Incidence of Cancer and Increasing Adoption of Targeted Therapy
5.2.2 Restraints
5.2.2.1 Unfavorable Regulatory and Reimbursement Scenario
5.2.2.2 High Amount of Capital Investments and Low Benefit-Cost Ratio
5.2.3 Opportunities
5.2.3.1 Companion Diagnostics
6 Immuno-Oncology Assays Market, By Product (Page No. - 33)
6.1 Introduction
6.2 Consumables
6.2.1 Consumables Segment Will Continue to Dominate the Immuno-Oncology Assays Market During the Forecast Period
6.3 Software
6.3.1 The Need to Deliver Accurate and Timely Analysis of Diagnostic Tests has Resulted in the Increased Adoption of Software
7 Immuno-Oncology Assays Market, By Technology (Page No. - 37)
7.1 Introduction
7.2 PCR
7.2.1 Emergence of Advanced PCR Technologies to Support Market Growth
7.3 Immunoassay
7.3.1 Immunoassays Have the Potential to Reduce Cancer Mortality Rate By Facilitating the Diagnosis of Cancer in the Early Stage
7.4 Ngs
7.4.1 Ngs Segment to Register the Highest Growth Rate During the Forecast Period
7.5 Flow Cytometry
7.5.1 Flow Cytometry Plays A Critical Role in Clinical Research Studies
7.6 Other Technologies
8 Immuno-Oncology Assays Market, By Indication (Page No. - 45)
8.1 Introduction
8.2 Lung Cancer
8.2.1 Increasing R&D Activities on Lung Immuno-Oncology Assays is A Key Market Driver
8.3 Colorectal Cancer
8.3.1 High Success Rate of Immuno-Oncology Assays in Crc Treatment Decisions to Drive Market Growth
8.4 Melanoma
8.4.1 Growing Cases of Melanoma to Drive Market Growth
8.5 Bladder Cancer
8.5.1 Bladder Cancer Segment to Witness Slower Growth Owing to the Limited Adoption of Immuno-Oncology Assays
8.6 Other Cancers
9 Immuno-Oncology Assays Market, By Application (Page No. - 52)
9.1 Introduction
9.2 Research Applications
9.2.1 Rising Prominence of Biomarker-Based Drug Development and Clinical Trials to Drive the Research Applications Market
9.3 Clinical Diagnostics
9.3.1 Benefits of Immuno-Oncology Assays are Driving Its Adoption in Clinical Diagnostics
10 Immuno-Oncology Assays Market, By Region (Page No. - 56)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.1.1 Increasing Demand for Immunotherapy Medicine Forms A Key Driver of Market Growth in the US
10.2.2 Canada
10.2.2.1 High Burden of Cancer to Drive the Demand for Immuno-Oncology Assays
10.3 Europe
10.3.1 Rising Focus on Biomarker Development in Several Eu Countries to Support Market Growth
10.4 Asia Pacific
10.4.1 Increasing Demand for Better Healthcare Services in Developing Economies Will Contribute to Market Growth
10.5 Rest of the World
11 Competitive Landscape (Page No. - 73)
11.1 Overview
11.2 Vendor Benchmarking
11.3 Competitive Leadership Mapping
11.3.1 Visionary Leaders
11.3.2 Innovators
11.3.3 Dynamic Differentiators
11.3.4 Emerging Companies
11.4 Market Ranking Analysis, 2017
11.5 Competitive Situation and Trends
11.5.1 Collaborations
11.5.2 Product Launches
11.5.3 Acquisitions
11.5.4 Expansions
12 Company Profiles (Page No. - 79)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 Thermo Fisher Scientific, Inc.
12.2 Roche Diagnostics
12.3 Agilent Technologies, Inc.
12.4 Illumina, Inc.
12.5 Nanostring Technologies, Inc.
12.6 Sartorius AG
12.7 Foundation Medicine
12.8 HTG Molecular Diagnostics, Inc.
12.9 Qiagen
12.10 Merck
12.11 Perkinelmer
*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. - 101)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Available Customizations
13.5 Related Reports
13.6 Author Details
List of Tables (63 Tables)
Table 1 Market, By Product, 2016–2024 (USD Million)
Table 2 Market for Consumables, By Region, 2016–2024 (USD Million)
Table 3 North America: Market for Consumables, By Country, 2016–2024 (USD Million)
Table 4 Market for Software, By Region, 2016–2024 (USD Million)
Table 5 North America: Market for Software, By Country, 2016–2024 (USD Million)
Table 6 Market, By Technology, 2016–2024 (USD Million)
Table 7 Market for PCR, By Region, 2016–2024 (USD Million)
Table 8 North America: Market for PCR, By Country, 2016–2024 (USD Million)
Table 9 Market for Immunoassay, By Region, 2016–2024 (USD Million)
Table 10 North America: Market for Immunoassay, By Country, 2016–2024 (USD Million)
Table 11 Market for Ngs, By Region, 2016–2024 (USD Million)
Table 12 North America: Market for Ngs, By Country, 2016–2024 (USD Million)
Table 13 Market for Flow Cytometry, By Region, 2016–2024 (USD Million)
Table 14 North America: Market for Flow Cytometry, By Country, 2016–2024 (USD Million)
Table 15 Market for Other Technologies, By Region, 2016–2024 (USD Million)
Table 16 North America: Market for Other Technologies, By Country, 2016–2024 (USD Million)
Table 17 Market, By Indication, 2016–2024 (USD Million)
Table 18 Market for Lung Cancer, By Region, 2016–2024 (USD Million)
Table 19 North America: Market for Lung Cancer, By Country, 2016–2024 (USD Million)
Table 20 Immun0-Oncology Assays Market for Colorectal Cancer, By Region, 2016–2024 (USD Million)
Table 21 North America: Immun0-Oncology Assays Market for Colorectal Cancer, By Country, 2016–2024 (USD Million)
Table 22 Immun0-Oncology Assays Market for Melanoma, By Region, 2016–2024 (USD Million)
Table 23 North America: Immun0-Oncology Assays Market for Melanoma, By Country, 2016–2024 (USD Million)
Table 24 Immun0-Oncology Assays Market for Bladder Cancer, By Region, 2016–2024 (USD Million)
Table 25 North America: Immun0-Oncology Assays Market for Bladder Cancer, By Country, 2016–2024 (USD Million)
Table 26 Market for Other Cancers, By Region, 2016–2024 (USD Million)
Table 27 North America: Market for Other Cancers, By Country, 2016–2024 (USD Million)
Table 28 Market, By Application, 2016–2024 (USD Million)
Table 29 Market for Research Applications, By Region, 2016–2024 (USD Million)
Table 30 North America: Market for Research Applications, By Country, 2016–2024 (USD Million)
Table 31 Market for Applications, By Clinical Diagnostics, 2016–2024 (USD Million)
Table 32 North America: Market for Clinical Diagnostics, By Country, 2016–2024 (USD Million)
Table 33 Market, By Region, 2016–2024 (USD Million)
Table 34 North America: Market, By Country, 2016–2024 (USD Million)
Table 35 North America: Market, By Product, 2016–2024 (USD Million)
Table 36 North America: Market, By Technology, 2016–2024 (USD Million)
Table 37 North America: Market, By Indication, 2016–2024 (USD Million)
Table 38 North America: Market, By Application, 2016–2024 (USD Million)
Table 39 US: Market, By Product, 2016–2024 (USD Million)
Table 40 US: Market, By Technology, 2016–2024 (USD Million)
Table 41 US: Market, By Indication, 2016–2024 (USD Million)
Table 42 US: Market, By Application, 2016–2024 (USD Million)
Table 43 Canada: Immuno-Oncology Assays Market, By Product, 2016–2024 (USD Million)
Table 44 Canada: Market, By Technology, 2016–2024 (USD Million)
Table 45 Canada: Market, By Indication, 2016–2024 (USD Million)
Table 46 Canada: Market, By Application, 2016–2024 (USD Million)
Table 47 Europe: Market, By Product, 2016–2024 (USD Million)
Table 48 Europe: Market, By Technology, 2016–2024 (USD Million)
Table 49 Europe: Market, By Indication, 2016–2024 (USD Million)
Table 50 Europe: Market, By Application, 2016–2024 (USD Million)
Table 51 APAC: Market, By Product, 2016–2024 (USD Million)
Table 52 APAC: Market, By Technology, 2016–2024 (USD Million)
Table 53 APAC: Immuno-Oncology Assays Market, By Indication, 2016–2024 (USD Million)
Table 54 APAC: Market, By Application, 2016–2024 (USD Million)
Table 55 RoW: Market, By Product, 2016–2024 (USD Million)
Table 56 RoW: Assays Market, By Technology, 2016–2024 (USD Million)
Table 57 RoW: Market, By Indication, 2016–2024 (USD Million)
Table 58 RoW: Market, By Application, 2016–2024 (USD Million)
Table 59 Vendor Benchmarking By Growth Strategy
Table 60 Collaborations, 2016–2018
Table 61 Product Launches, 2016–2018
Table 62 Acquisitions, 2016-2018
Table 63 Expansions, 2015 to 2018
List of Figures (30 Figures)
Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Data Triangulation
Figure 6 Market, By Application, 2018 vs 2024 (USD Million)
Figure 7 Market, By Product, 2018 vs 2024 (USD Million)
Figure 8 Market, By Indication, 2018 vs 2024 (USD Million)
Figure 9 Market, By Technology, 2018 vs 2024 (USD Million)
Figure 10 Geographical Snapshot of the Immuno-Oncology Assays Market
Figure 11 Increasing Adoption of Targeted Therapy Over Traditional Therapy is A Key Driver for the Immuno-Oncology Assays Market
Figure 12 Consumables Segment to Account for Largest Share in North American Immuno-Oncology Assays Market
Figure 13 Research Applications to Continue to Dominate the Immuno-Oncology Assays Market in 2024
Figure 14 PCR Segment Will Continue to Dominate the Immuno-Oncology Assays Market in 2024
Figure 15 APAC Will Be the Fastest-Growing Market From 2018 to 2024
Figure 16 Immuno-Oncology Assays Market: Drivers, Restraints, and Opportunities
Figure 17 North America: Immuno-Oncology Assays Market Snapshot
Figure 18 Asia Pacific: Immuno-Oncology Assays Market Snapshot
Figure 19 Immuno-Oncology Assays Market (Global), Competitive Leadership Mapping, 2017
Figure 20 Rank of Companies in the Global Immuno-Oncology Assays Market, 2017
Figure 21 Thermo Fisher Scientific: Company Snapshot (2017)
Figure 22 Roche Diagnostics: Company Snapshot (2017)
Figure 23 Agilent Technologies: Company Snapshot (2017)
Figure 24 Illumina: Company Snapshot (2017)
Figure 25 Nanostring Technologies: Company Snapshot (2017)
Figure 26 Sartorius AG: Company Snapshot (2017)
Figure 27 HTG Molecular Diagnostics: Company Snapshot (2017)
Figure 28 Qiagen: Company Snapshot (2017)
Figure 29 Merck: Company Snapshot (2017)
Figure 30 Perkinelmer: Company Snapshot (2017)
The study involved four major activities in estimating the current market size for immuno-oncology assays. Exhaustive research was conducted to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
Secondary Research
In the secondary research process, various sources such as Bloomberg BusinessWeek, Forbes, and Dun & Bradstreet were referred to, so as to identify and collect information useful for a technical, market-oriented, and commercial study of the immuno-oncology assays market. These secondary sources include annual reports, press releases & investor presentations of companies, World Health Organization, World Bank, Centers for Disease Control and Prevention, National Institutes of Health, Canadian Institute for Health Information, National Cancer Institute, European Association for Cancer Research, Australian Cancer Research Foundation, GLOBOCAN, and American Cancer Society. Secondary research was mainly used to obtain key information about the industry’s supply chain, the total pool of key players, market classification, and segmentation according to industry trends to the bottom-most level and regional markets. It was also used to obtain information about the key developments from a market-oriented perspective.
Primary Research
The immuno-oncology assays market comprises several stakeholders such as raw material suppliers, manufacturers of immuno-oncology assays, and regulatory organizations in the supply chain. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The primary interviewees from the demand side include key opinion leaders in drug manufacturing, research laboratories, and academic institutes. The primary sources from the supply side include key opinion leaders, distributors, and immuno-oncology assay manufacturers. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. Given below is the breakdown of primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both the top-down and bottom-up approaches were used to estimate and validate the total size of the immuno-oncology assays market. These approaches were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- Key players were identified through extensive secondary research.
- The immuno-oncology assays industry’s value chain and market size, in terms of value, was determined through primary and secondary research.
- All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources.
- All possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to obtain the final quantitative and qualitative data.
Data Triangulation
After arriving at the overall market size—using the market size estimation processes explained above—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides of the immuno-oncology assays industry.
Report Objectives
- To define, segment, and estimate the global market size for immuno-oncology assays
- To understand the structure of the immuno-oncology assays market by identifying its various subsegments
- To provide detailed information about the key factors influencing the growth of the market (drivers, restraints, and opportunities)
- To estimate the size of the market and its submarkets, in terms of value and volume, with respect to four regions (along with their respective key countries)
- To profile key players and comprehensively analyze their core competencies
- To understand the competitive landscape and identify the major growth strategies adopted by players across key regions
- To analyze the competitive developments such as expansions & investments, product launches, and acquisitions in the immuno-oncology assays market
Scope of the Report
|
Report Metric |
Details |
|
Market size available for years |
2016–2024 |
|
Base year considered |
2017 |
|
Forecast period |
2018–2024 |
|
Forecast units |
Values (USD Million) |
|
Segments covered |
Product, Technology, Application, Indication, and Region |
|
Geographies covered |
North America, Europe, APAC, and RoW |
|
Companies covered |
Thermo Fischer Scientific (US), Roche Diagnostics (Switzerland), Agilent Technologies (US), and Illumina (US). 10 major players covered, in total. |
On the basis of Product, the immuno-oncology assays market is segmented as follows:
- Consumables
- Software
On the basis of Technology, the immuno-oncology assays market is segmented as follows:
- Immunoassay
- PCR
- NGS
- Flow Cytometry
- Other Technologies
On the basis of Indication, the immuno-oncology assays market is segmented as follows:
- Lung Cancer
- Colorectal Cancer
- Melanoma
- Bladder Cancer
- Other Cancers
On the basis of application, the immuno-oncology assays market is segmented as follows:
- Research Applications
- Clinical Diagnostics
On the basis of region, the immuno-oncology assays market is segmented as follows:
- North America
- US
- Canada
- Europe
- Asia Pacific
- RoW
Available Customizations
With the given market data, MarketsandMarkets offers customizations according to company-specific scientific needs.
The following customization options are available for the report:
Regional Analysis
- Further breakdown of the European immuno-oncology assays market, by key country
- Further breakdown of the Asia Pacific immuno-oncology assays market, by key country
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Immuno Oncology Assays Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Immuno Oncology Assays Market